Cytokinetics director plans 2,000-share sale

CYTOKINETICS, INCORPORATED (CYTK) received a notice that director Robert Landry plans to sell 2,000 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC.

Available on EDGAR 09/11/2026 - 04:30 PM EDT Accepted by SEC EDGAR 09/11/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CYTOKINETICS, INCORPORATED (CYTK) received a notice that director Robert Landry plans to sell 2,000 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC. The planned sale has an indicated aggregate market value of $147,240 as of September 11, 2026.

Key Figures

Shares proposed to be sold: 2,000 shares Aggregate market value: $147,240 Planned sale date reference: September 11, 2026 +1 more

4 metrics

Shares proposed to be sold 2,000 shares Common stock to be sold for the account of Robert Landry under Rule 144

Aggregate market value $147,240 Value for 2,000 CYTK common shares as of September 11, 2026

Planned sale date reference September 11, 2026 Date associated with the proposed NASDAQ sale of 2,000 common shares

Acquisition date of RSUs May 14, 2026 Restricted Stock Units from issuer listed as source of the 2,000 shares

Key Terms

Rule 144, Restricted Stock Units, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"Common | 05/14/2026 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

aggregate market value financial

"Common ... 2000 | 147240.00 ... 09/11/2026 | NASDAQ"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for CYTK disclose?

It discloses that director Robert Landry intends to sell 2,000 shares of Cytokinetics common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $147,240 as of September 11, 2026.

How many CYTK shares are covered by Robert Landry’s planned sale?

The notice covers a proposed sale of 2,000 shares of CYTK common stock. These shares are identified as originating from Restricted Stock Units and are to be sold for the account of Robert Landry.

What is the indicated value of the CYTK shares in this Form 144?

The Form 144 lists an aggregate market value of $147,240 for the 2,000 CYTK common shares proposed to be sold, based on information as of September 11, 2026 on NASDAQ.

Who is the broker for the CYTK shares to be sold under this Form 144?

The planned sale of 2,000 CYTK common shares is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, NY 10004.

What type of CYTK securities is Robert Landry planning to sell?

Robert Landry plans to sell common stock of Cytokinetics. The Form 144 notes that the shares come from Restricted Stock Units acquired from the issuer on May 14, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001585160
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CYTOKINETICS, INCORPORATED
SEC File Number	000-50633
Address of Issuer	350 Oyster Point Blvd. SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	6506243000
Name of Person for Whose Account the Securities are To Be Sold	ROBERT LANDRY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2000	147240.00	139023418	09/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/14/2026	Restricted Stock Units	Issuer			2000	05/14/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/11/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Robert Landry
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)